The safety profile of DUPIXENT in patients aged 12 to 17 years through Week 16 was similar to the safety profile from studies in adults with atopic dermatitis.
The long‑term safety of DUPIXENT in adolescents was assessed in an open‑label extension trial (Trial 7) through Week 522
Discontinuation rates in adolescents due to adverse events with DUPIXENT were comparable to those with placebo1
of adolescent patients treated with DUPIXENT discontinued treatment through Week 16
of adolescent patients treated with placebo discontinued through Week 16
Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs and/or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment.
Avoid use of live vaccines with DUPIXENT2
DUPIXENT is not a steroid treatment or an immunosuppressant2
There is no requirement for initial lab testing or ongoing lab monitoring according to the Prescribing Information2
EASI, Eczema Area and Surface Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.